Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Protagonist Therapeutics Inc PTGX

Healthcare Biotechnology
Protagonist Therapeutics, Inc. is a biopharmaceutical company. The Company uses its peptide-based chemical entities rusfertide and JNJ-2113 in different stages of development, all derived from its proprietary discovery technology platform. The Company’s clinical programs fall into two categories of diseases: hematology and blood disorders, and inflammatory and immunomodulatory diseases. Its... see more

Recent & Breaking News (NDAQ:PTGX)

Protagonist Therapeutics to Present at the Stifel 2017 Healthcare Conference

PR Newswire November 1, 2017

Protagonist Therapeutics Prices Public Offering of Common Stock

PR Newswire October 11, 2017

9 Stocks Moving In Wednesday's After-Hours Session

Benzinga.com  October 11, 2017

Protagonist Therapeutics Announces Proposed Public Offering of Common Stock

PR Newswire October 11, 2017

Protagonist Therapeutics Announces Preliminary Phase 1 Study Results with Novel Hepcidin Mimetic, PTG-300

PR Newswire September 20, 2017

Protagonist Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference

PR Newswire September 11, 2017

Protagonist Therapeutics Announces Closing of Janssen License and Collaboration Agreement for PTG-200 and Receipt of $50 Million Payment

PR Newswire August 24, 2017

Protagonist Therapeutics Reports Second Quarter 2017 Financial Results and Business Highlights

PR Newswire August 8, 2017

Protagonist Therapeutics Appoints Five Prime Therapeutics CEO, Lewis T. "Rusty" Williams, to its Board of Directors

PR Newswire June 8, 2017

Mid-Afternoon Market Update: Protagonist Therapeutics Surges After Agreement With Janssen; Ambarella Shares Plunge

Benzinga.com  May 30, 2017

Protagonist Therapeutics Spikes Sharply After Agreement With Janssen

Benzinga.com  May 30, 2017

Protagonist Therapeutics Enters into Worldwide Agreement with Janssen to Co-Develop and Commercialize PTG-200 for Inflammatory Bowel Disease

PR Newswire May 30, 2017

Protagonist Therapeutics Initiates Phase 1 Study with Novel Hepcidin Mimetic, PTG-300

PR Newswire May 25, 2017

Protagonist Therapeutics Receives $1.34 Million SBIR Funding for Development of Biomarkers of IL-23 Receptor Antagonist Activity

PR Newswire May 24, 2017

Protagonist Therapeutics Reports First Quarter 2017 Financial Results

PR Newswire May 10, 2017

Key Patent Issues Covering Protagonist Therapeutics' Oral Peptide IL-23 Receptor Antagonists, including the Development Candidate PTG-200

PR Newswire May 4, 2017

Protagonist Therapeutics Announces PTG-200 Data Accepted for Oral Presentation at Digestive Diseases Week

PR Newswire April 20, 2017

Protagonist Therapeutics to Present at the Oppenheimer & Co. Healthcare Conference

PR Newswire March 9, 2017

Protagonist Therapeutics Reports Fourth Quarter and Year-End 2016 Financial Results

PR Newswire March 7, 2017

Protagonist Therapeutics to Present at the Barclays Global Healthcare Conference

PR Newswire March 2, 2017